Valion Bio
VBIO
2 hedge funds and large institutions have $329K invested in Valion Bio in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
0.79% more ownership
Funds ownership: 1.31% → 2.1% (+0.79%)
33% less capital invested
Capital invested by funds: $492K → $329K (-$163K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$68K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$60K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$42K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$18K |
VBIO Hedge Fund Activity: Q1 2022 in Review
2 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2022, worth a combined $329K — down 33% from $492K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new VBIO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $245K. The largest seller was Ergoteles, cutting an estimated $68K.
- 2 institutional investors held Valion Bio (VBIO) as of Q1 2022, up from 1 in Q4 2021.
- Funds reported $329K of Valion Bio stock for Q1 2022, down 33% quarter-over-quarter.
- 1 fund opened new Valion Bio positions in Q1 2022 and 0 closed out, a net change of +1 holder.
- The largest Valion Bio buyer in Q1 2022 was Renaissance Technologies, an estimated $245K added.
- The largest Valion Bio seller in Q1 2022 was Ergoteles, an estimated $68K sold.
Based on aggregated 13F filings for Q1 2022.